7 Analysts Have This to Say About Agios Pharmaceuticals
Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings within the last quarter:
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Goldman Sachs Maintains Sell on Agios Pharmaceuticals, Lowers Price Target to $23
Goldman Sachs maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Sell and lowers the price target from $37 to $23.
HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $96
HC Wainwright & Co. analyst Michael King maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $98 to $96.
RBC Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $67
RBC Capital analyst Kennen MacKay maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Outperform and raises the price target from $61 to $67.
Analyst Ratings For Agios Pharmaceuticals
Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings within the last quarter:
SVB Leerink Maintains Market Perform on Agios Pharmaceuticals, Lowers Price Target to $30
SVB Leerink analyst Andrew Berens maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Market Perform and lowers the price target from $32 to $30.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.